The discovery of natalizumab, a potent therapeutic for multiple sclerosis.

Multiple sclerosis (MS) is the major inflammatory demyelinating disease of the central nervous system. There is strong evidence that an immune response in the brain is a critical component of the disease. In 1992, in a collaboration between academia and biotechnology, my colleagues and I showed that α4 integrin was the critical molecule involved in the homing of immune cells into the inflamed brain. Was it sheer luck that these results led to the development of a drug for MS?
AuthorsLawrence Steinman
JournalThe Journal of cell biology (J Cell Biol) Vol. 199 Issue 3 Pg. 413-6 (Oct 29 2012) ISSN: 1540-8140 [Electronic] United States
PMID23109666 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Natalizumab
  • Integrin alpha4
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Humans
  • Integrin alpha4 (immunology)
  • Multiple Sclerosis (drug therapy, immunology)
  • Natalizumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: